Quantcast

Latest Synthetic Biologics Inc. Stories

2014-06-30 08:29:30

-- Company Expects to Initiate C. difficile Clinical Trials in 2014 -- ROCKVILLE, Md., June 30, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating...

2014-06-25 08:29:57

-- Company's License Covers C-IBS, Type 2 Diabetes and Obesity -- ROCKVILLE, Md., June 25, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today announced that researchers at Cedars-Sinai Medical Center (Cedars-Sinai) found that eradication of breath methane and reduction of intestinal levels of the most common methanogenic...

2014-06-10 04:22:10

-- Study to Define Impact of Beta-Lactam Antibiotics on Intestinal Bacteria -- ROCKVILLE, Md. and PARIS, June 10, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced...

2014-05-20 16:26:18

ROCKVILLE, Md., May 20, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 3(rd) Annual Marcum LLP MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel. Mr. Riley is scheduled to present at 4:30 p.m. (Eastern Time)....

2014-05-15 08:31:13

-- Conference Call Today, May 15, 2014, at 8:30 a.m. (EDT) -- ROCKVILLE, Md., May 15, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today reported financial results for the three months ended March 31, 2014, and provided an operational progress update. http://photos.prnewswire.com/prnvar/20130522/MM19465LOGO Recent Operational Highlights...

2014-05-09 08:25:42

-- Conference Call Scheduled for Thursday, May 15, 2014, at 8:30 am EDT -- ROCKVILLE, Md., May 9, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it intends to release its financial results for the three months ended March 31, 2014 on Thursday, May 15, 2014. The Company will hold an investor conference call on...

2014-05-08 08:31:53

ROCKVILLE, Md., May 8, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it has been granted new patents in Europe and has received a notice of allowance in Australia that provide composition of matter coverage for various aspects of its C. difficile (C. diff) program. The Company's extensive C. diff patent estate...

2014-05-06 16:27:36

LONDON, May 6, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Synthetic Biology Industryhttp://www.reportbuyer.com/pharma_healthcare/biotechnology/synthetic_biology.htmlThis report analyzes the worldwide markets for Synthetic Biology in US$ Thousands by the following Application Areas: Energy & Chemicals, Biotechnology & Pharmaceuticals, and Others. The report provides separate comprehensive analytics for theUS, Canada, Japan, Europe,...

2014-04-30 08:31:49

-- Conference Call Scheduled for Today, April 30, 2014 at 9 AM ET-- ROCKVILLE, Md., April 30, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, will host a conference call today to discuss in further detail the topline Phase II study results of Trimesta(TM) (oral estriol), which the Company is developing as a once-daily adjunctive...

2014-04-29 16:31:14

-- UCLA Researcher Reports Adjunctive Trimesta was Associated with Reduced Relapse Rate of 47 Percent -- ROCKVILLE, Md., April 29, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, reported today that the University of California, Los Angeles (UCLA) School of Medicine announced preliminary, positive topline data from the Phase II...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related